Cellular epigenetic machinery

The cellular epigenetic machinery encompasses a diverse array of enzymes and proteins responsible for the heritable and reversible regulation of gene expression that occurs without changes to the primary DNA sequence (Source: NIH/National Human Genome Research Institute). This system is functionally organized into 'writers' that deposit chemical marks, 'erasers' that remove them, and 'readers' that interpret these marks to influence chromatin structure and transcriptional activity (Source: Nature Reviews Drug Discovery, 2012). Proper functioning of this machinery is essential for normal development, cellular differentiation, and maintaining genomic stability (Source: PubMed, PMC6147077). Dysregulation of epigenetic processes is a fundamental driver in various pathologies, most notably in oncology, where it facilitates the silencing of tumor suppressor genes and the activation of oncogenic pathways (Source: PubMed, PMC4251063). Therapeutic strategies targeting the epigenetic machinery, often referred to as 'epidrugs,' aim to restore normal gene expression patterns and have shown significant clinical efficacy in hematologic malignancies and certain solid tumors (Source: FDA, Drug Approval Databases). However, because these targets often regulate broad networks of genes, achieving high specificity and managing systemic toxicity remain significant challenges in drug development.

Other names

Epigenetic regulatory machineryEpigenomeChromatin-modifying machineryEpigenetic writers, readers, and erasers

Inhibition of histone deacetylases (HDACs), DNA methyltransferases (DNMTs), histone methyltransferases (HMTs), and bromodomain and extra-terminal (BET) proteins to modulate gene expression patterns and restore normal cellular phenotypes (Source: Nature Reviews Drug Discovery, 2012).